Data about higher doses that are injected less often come as the original 2-milligram dose of Eylea is facing an increasing ...

Rapid weight loss from the glucagon-like peptide 1 (GLP-1s) can reduce fat tissue in face that makes for a smooth, more ...

In the threat versus opportunity session, Cecilia and Aaron Lee of the University of Washington staked out opposing positions ...

Presenters at a myth breakers session at the American Academy of Ophthalmology took aim at some prevailing notions.

The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several months and in early 2025, according to Kaelyn Boss, who gave an oncology drug ...

Children with serious eye conditions are at an increased risk of developing mental health conditions, including schizophrenia ...

Harmony Garges, M.D, senior vice president, chief medical officer and head of global medical at ViiV Healthcare, highlighted ...

Enrollment goals for the U.S. part of the sutdy are 45% Black participants, 45% Hispanic participants and 10% Native American ...

Patients self-identified as members of the minority group that the study was designed to enroll, according to Jeremiah Brown, ...

Only 15% of those who start a glucagon-like peptide 1 (GLP-1) for weight loss are still taking it two years according to ...

Chronic and acute graft-versus-host disease are managed differently, affect different organs, and impact patients in ...

One of two new studies found most patients doing well six years after treatment. Another study found blood cancers in 17% of ...